Special report: Medical cannabis product play MGC Pharma has secured a key talent for its medical advisory board, bringing on leading neurologist and epileptologist Associate Professor Wendyl D’Souza.

The company (ASX:MXC) has recently seen a number of key wins on its path to commercialise its CannEpil™ product, a phytocannabinoid-based medication for the treatment of refractory epilepsy.

Earlier this month, the company secured Good Manufacturing Practice (GMP) certification for its European production facility and can now product pharmaceutical grade medicinal cannabis products.

Associate Professor D’Souza will work alongside Professors Uri Kramer and David Neubauer to lead the company’s research projects into cannabis-based medicines as a treatment for neurological disorders.

The medical advisory board appointment is an important one for the company, given Associate Professor D’Souza’s clinical experience. He has treated 3,000 epilepsy patients across Australia, and will facilitate patient access to CannEpil™ in Australia.

Associate Professor Wendyl D’Souza

He currently works in Neuroloempidemiology and Health Services Research at St Vincent’s Hospital and the University of Melbourne and has 15 years’ clinical experience in researching neurological disorders.

He has previously secured $5 million for his research projects.

Associate Professor D’Souza will help lead a project into the further development of CannEpil and the next generation of medical cannabis medicines for MGC Pharma.

“We are delighted to welcome Wendyl D’Souza on board and think he will be a great asset to MGC Pharma, and for the introduction of CannEpil in Australia. Wendyl is a world-renowned neurology expert and we look forward to his input on the projects we are currently working on,” MGC Pharma managing director Roby Zomer said of his appointment.


This special report is brought to you by MGC Pharma. 

This advice has been prepared without taking into account your objectives, financial situation or needs. You should, therefore, consider the appropriateness of the advice, in light of your own objectives, financial situation or needs, before acting on the advice.

If this advice relates to the acquisition, or possible acquisition, of a particular financial product, the recipient should obtain a Product Disclosure Statement (PDS) relating to the product and consider the PDS before making any decision about whether to acquire the product.